Challenges of modifying disease progression in prediagnostic Parkinson's disease

Fearnley, 1991, Ageing and Parkinson's disease: substantia nigra regional selectivity, Brain, 114, 2283, 10.1093/brain/114.5.2283 Irwin, 2013, Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies, Nat Rev Neurosci, 14, 626, 10.1038/nrn3549 Tolosa, 2015, Pharmacological management of Parkinson's disease, 86 Poewe, 2009, The clinical progression of Parkinson's disease, Parkinsonism Relat Disord, 15, S28, 10.1016/S1353-8020(09)70831-4 Hely, 2005, Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years, Mov Disord, 20, 190, 10.1002/mds.20324 1989, Effect of deprenyl on the progression of disability in early Parkinson's disease, N Engl J Med, 321, 1364, 10.1056/NEJM198911163212004 2007, A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease, Neurology, 68, 20, 10.1212/01.wnl.0000250355.28474.8e Olanow, 2009, A double-blind, delayed-start trial of rasagiline in Parkinson's disease, N Engl J Med, 361, 1268, 10.1056/NEJMoa0809335 Braak, 2003, Staging of brain pathology related to sporadic Parkinson's disease, Neurobiol Aging, 24, 197, 10.1016/S0197-4580(02)00065-9 Dexter, 2013, Parkinson disease: from pathology to molecular disease mechanisms, Free Radic Biol Med, 62, 132, 10.1016/j.freeradbiomed.2013.01.018 Blesa, 2012, Classic and new animal models of Parkinson's disease, J Biomed Biotechnol, 2012, 845618, 10.1155/2012/845618 Ryan, 2015, Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease, Trends Biochem Sci, 40, 200, 10.1016/j.tibs.2015.02.003 Celardo, 2014, Unravelling mitochondrial pathways to Parkinson's disease, Br J Pharmacol, 171, 1943, 10.1111/bph.12433 Schapira, 1990, Mitochondrial complex I deficiency in Parkinson's disease, J Neurochem, 54, 823, 10.1111/j.1471-4159.1990.tb02325.x Simcox, 2013, Monitoring mitochondrial dynamics and complex I dysfunction in neurons: implications for Parkinson's disease, Biochem Soc Trans, 41, 1618, 10.1042/BST20130189 Schapira, 2010, Molecular and clinical prodrome of Parkinson disease: implications for treatment, Nat Rev Neurol, 6, 309, 10.1038/nrneurol.2010.52 Savica, 2009, Medical records documentation of constipation preceding Parkinson disease: a case-control study, Neurology, 73, 1752, 10.1212/WNL.0b013e3181c34af5 Fang, 2010, Depression and the subsequent risk of Parkinson's disease in the NIH-AARP Diet and Health Study, Mov Disord, 25, 1157, 10.1002/mds.23092 Ross, 2008, Association of olfactory dysfunction with risk for future Parkinson's disease, Ann Neurol, 63, 167, 10.1002/ana.21291 Ross, 2012, Pre-motor features of Parkinson's disease: the Honolulu-Asia Aging Study experience, Parkinsonism Relat Disord, 18, S199, 10.1016/S1353-8020(11)70062-1 Schrag, 2015, Prediagnostic presentations of Parkinson's disease in primary care: a case-control study, Lancet Neurol, 14, 57, 10.1016/S1474-4422(14)70287-X Noyce, 2012, Meta-analysis of early nonmotor features and risk factors for Parkinson disease, Ann Neurol, 72, 893, 10.1002/ana.23687 Ponsen, 2004, Idiopathic hyposmia as a preclinical sign of Parkinson's disease, Ann Neurol, 56, 173, 10.1002/ana.20160 Iranzo, 2014, Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients, PLoS One, 9, e89741, 10.1371/journal.pone.0089741 Postuma, 2012, How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder, Brain, 135, 1860, 10.1093/brain/aws093 Tolosa, 2009, Diagnosis and the premotor phase of Parkinson disease, Neurology, 72, S12, 10.1212/WNL.0b013e318198db11 Wu, 2011, Preclinical biomarkers of Parkinson disease, Arch Neurol, 68, 22, 10.1001/archneurol.2010.321 Iranzo, 2006, Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study, Lancet Neurol, 5, 572, 10.1016/S1474-4422(06)70476-8 Sommer, 2004, Detection of presymptomatic Parkinson's disease: combining smell tests, transcranial sonography, and SPECT, Mov Disord, 19, 1196, 10.1002/mds.20141 Mirelman, 2011, Gait alterations in healthy carriers of the LRRK2 G2019S mutation, Ann Neurol, 69, 193, 10.1002/ana.22165 San Luciano, 2010, Clinical expression of LRRK2 G2019S mutations in the elderly, Mov Disord, 25, 2571, 10.1002/mds.23330 Beavan, 2015, Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort, JAMA Neurol, 72, 201, 10.1001/jamaneurol.2014.2950 Hawkes, 2003, Olfaction in neurodegenerative disorder, Mov Disord, 18, 364, 10.1002/mds.10379 Fernández-Santiago, 2015, MicroRNA association with synucleinopathy conversion in rapid eye movement behavior disorder, Ann Neurol, 77, 895, 10.1002/ana.24384 Marras, 2011, Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers, Neurology, 77, 325, 10.1212/WNL.0b013e318227042d Nandhagopal, 2008, Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study, Neurology, 71, 1790, 10.1212/01.wnl.0000335973.66333.58 Schenck, 1996, Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder, Neurology, 46, 388, 10.1212/WNL.46.2.388 Fereshtehnejad, 2015, New clinical subtypes of Parkinson disease and their longitudinal progression: a prospective cohort comparison with other phenotypes, JAMA Neurol, 72, 863, 10.1001/jamaneurol.2015.0703 Berg, 2013, The PRIPS study: screening battery for subjects at risk for Parkinson's disease, Eur J Neurol, 20, 102, 10.1111/j.1468-1331.2012.03798.x Jennings, 2014, Imaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study, Neurology, 83, 1739, 10.1212/WNL.0000000000000960 Siderowf, 2012, Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome Study, Mov Disord, 27, 406, 10.1002/mds.24892 Gaenslen, 2014, Prodromal features for Parkinson's disease–baseline data from the TREND study, Eur J Neurol, 21, 766, 10.1111/ene.12382 Lerche, 2015, Reasons for mild parkinsonian signs—which constellation may indicate neurodegeneration?, Parkinsonism Relat Disord, 21, 126, 10.1016/j.parkreldis.2014.11.018 Noyce, 2014, PREDICT-PD: identifying risk of Parkinson's disease in the community: methods and baseline results, J Neurol Neurosurg Psychiatry, 85, 31, 10.1136/jnnp-2013-305420 2011, The Parkinson Progression Marker Initiative (PPMI), Prog Neurobiol, 95, 629, 10.1016/j.pneurobio.2011.09.005 Berg, 2015, MDS research criteria for prodromal Parkinson's disease, Mov Disord, 30, 1600, 10.1002/mds.26431 Schneider, 2015, Can we use peripheral tissue biopsies to diagnose Parkinson's disease? A review of the literature, Eur J Neurol, 23, 247, 10.1111/ene.12753 1993, Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease, N Engl J Med, 328, 176, 10.1056/NEJM199301213280305 Schapira, 2013, Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial, Lancet Neurol, 12, 747, 10.1016/S1474-4422(13)70117-0 Aviles-Olmos, 2014, Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease, J Parkinsons Dis, 4, 337, 10.3233/JPD-140364 Knight, 2007, Animal experiments scrutinised: systematic reviews demonstrate poor human clinical and toxicological utility, ALTEX, 24, 320, 10.14573/altex.2007.4.320 Busche, 2015, Decreased amyloid-β and increased neuronal hyperactivity by immunotherapy in Alzheimer's models, Nat Neurosci, 18, 1725, 10.1038/nn.4163 Johnson, 2010, Huntington's disease: progress toward effective disease-modifying treatments and a cure, Hum Mol Genet, 19, R98, 10.1093/hmg/ddq148 Galimberti, 2011, Disease-modifying treatments for Alzheimer's disease, Ther Adv Neurol Disord, 4, 203, 10.1177/1756285611404470 Siciliano, 2010, Clinical trials for neuroprotection in ALS, CNS Neurol Disord Drug Targets, 9, 305, 10.2174/187152710791292648 Hughes, 1992, Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases, J Neurol Neurosurg Psychiatry, 55, 181, 10.1136/jnnp.55.3.181 Buchman, 2012, Nigral pathology and parkinsonian signs in elders without Parkinson disease, Ann Neurol, 71, 258, 10.1002/ana.22588 Johansen, 2011, Subclinical signs in LRRK2 mutation carriers, Parkinsonism Relat Disord, 17, 528, 10.1016/j.parkreldis.2011.04.014 Tabrizi, 2012, Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data, Lancet Neurol, 11, 42, 10.1016/S1474-4422(11)70263-0 Marek, 2009, Can we image premotor Parkinson disease?, Neurology, 72, S21, 10.1212/WNL.0b013e318198df97 Hilker, 2005, Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity, Arch Neurol, 62, 378, 10.1001/archneur.62.3.378 Scherfler, 2007, Role of DAT-SPECT in the diagnostic work up of parkinsonism, Mov Disord, 22, 1229, 10.1002/mds.21505 Iranzo, 2011, Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study, Lancet Neurol, 10, 797, 10.1016/S1474-4422(11)70152-1 Winogrodzka, 2001, [123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease, J Neural Transm (Vienna), 108, 1011, 10.1007/s007020170019 Pirker, 2002, Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study, Mov Disord, 17, 45, 10.1002/mds.1265 Seibyl, 1997, Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients, J Nucl Med, 38, 1453 Pavese, 2009, Imaging neurodegeneration in Parkinson's disease, Biochim Biophys Acta, 1792, 722, 10.1016/j.bbadis.2008.10.003 Pyatigorskaya, 2014, A review of the use of magnetic resonance imaging in Parkinson's disease, Ther Adv Neurol Disord, 7, 206, 10.1177/1756285613511507 Brockmann, 2011, Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers, Mov Disord, 26, 2335, 10.1002/mds.23991 Scherfler, 2011, White and gray matter abnormalities in idiopathic rapid eye movement sleep behavior disorder: a diffusion-tensor imaging and voxel-based morphometry study, Ann Neurol, 69, 400, 10.1002/ana.22245 Sharma, 2013, Biomarkers in Parkinson's disease (recent update), Neurochem Int, 63, 201, 10.1016/j.neuint.2013.06.005 Foulds, 2013, A longitudinal study on α-synuclein in blood plasma as a biomarker for Parkinson's disease, Sci Rep, 3, 2540, 10.1038/srep02540 Berg, 2013, Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease, Mov Disord, 28, 216, 10.1002/mds.25192 Iranzo, 2010, Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study, Lancet Neurol, 9, 1070, 10.1016/S1474-4422(10)70216-7 Postuma, 2015, Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials, Neurology, 84, 1104, 10.1212/WNL.0000000000001364 Sierra, 2013, Olfaction and imaging biomarkers in premotor LRRK2 G2019S-associated Parkinson disease, Neurology, 80, 621, 10.1212/WNL.0b013e31828250d6 Vilas, 2015, Clinical and imaging markers in premotor LRRK2 G2019S mutation carriers, Parkinsonism Relat Disord, 21, 1170, 10.1016/j.parkreldis.2015.08.007 Huleatt, 2015, Novel arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson's disease, J Med Chem, 58, 1400, 10.1021/jm501722s Wang, 2015, Tanshinone I selectively suppresses pro-inflammatory genes expression in activated microglia and prevents nigrostriatal dopaminergic neurodegeneration in a mouse model of Parkinson's disease, J Ethnopharmacol, 164, 247, 10.1016/j.jep.2015.01.042 Zhang, 2015, Examining the neuroprotective effects of protocatechuic acid and chrysin on in vitro and in vivo models of Parkinson disease, Free Radic Biol Med, 84, 331, 10.1016/j.freeradbiomed.2015.02.030 Spencer, 2014, ESCRT-mediated uptake and degradation of brain-targeted α-synuclein single chain antibody attenuates neuronal degeneration in vivo, Mol Ther, 22, 1753, 10.1038/mt.2014.129 Tran, 2014, A-synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration, Cell Reports, 7, 2054, 10.1016/j.celrep.2014.05.033 Patel, 2005, Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study, Ann Neurol, 57, 298, 10.1002/ana.20374 Marks, 2008, Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial, Lancet Neurol, 7, 400, 10.1016/S1474-4422(08)70065-6 Marks, 2010, Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial, Lancet Neurol, 9, 1164, 10.1016/S1474-4422(10)70254-4 Mortiboys, 2013, Ursocholanic acid rescues mitochondrial function in common forms of familial Parkinson's disease, Brain, 136, 3038, 10.1093/brain/awt224 Alcalay, 2012, The association between Mediterranean diet adherence and Parkinson's disease, Mov Disord, 27, 771, 10.1002/mds.24918 Chao, 2012, Nutraceuticals and their preventive or potential therapeutic value in Parkinson's disease, Nutr Rev, 70, 373, 10.1111/j.1753-4887.2012.00484.x Duncan, 2014, Are the effects of community-based dance on Parkinson disease severity, balance, and functional mobility reduced with time? A 2-year prospective pilot study, J Altern Complement Med, 20, 757, 10.1089/acm.2012.0774 Shu, 2014, Aerobic exercise for Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials, PLoS One, 9, e100503, 10.1371/journal.pone.0100503 Frazzitta, 2015, Intensive rehabilitation treatment in early Parkinson's disease: a randomized pilot study with a 2-year follow-up, Neurorehabil Neural Repair, 29, 123, 10.1177/1545968314542981 Fisher, 2013, Treadmill exercise elevates striatal dopamine D2 receptor binding potential in patients with early Parkinson's disease, Neuroreport, 24, 509, 10.1097/WNR.0b013e328361dc13 Park, 2014, Effects of a formal exercise program on Parkinson's disease: a pilot study using a delayed start design, Parkinsonism Relat Disord, 20, 106, 10.1016/j.parkreldis.2013.10.003 2013, World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects, JAMA, 310, 2191, 10.1001/jama.2013.281053 Rosas, 2014, PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease, Neurology, 82, 850, 10.1212/WNL.0000000000000187 Moulder, 2013, Dominantly Inherited Alzheimer Network: facilitating research and clinical trials, Alzheimers Res Ther, 5, 48, 10.1186/alzrt213 Corti, 2009, Neurodegeneration in Parkinson's disease: genetics enlightens physiopathology, J Neural Transm Suppl, 73, 215 Lang, 2010, Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future, Nat Med, 16, 1223, 10.1038/nm.2220